Massachusetts Financial Services Co. MA Reduces Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Massachusetts Financial Services Co. MA lowered its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 29.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,415 shares of the company's stock after selling 28,756 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.10% of Nurix Therapeutics worth $1,560,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Amalgamated Bank grew its holdings in shares of Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after acquiring an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock worth $54,000 after purchasing an additional 559 shares during the last quarter. GAMMA Investing LLC grew its stake in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock valued at $95,000 after purchasing an additional 3,424 shares during the period. International Assets Investment Management LLC increased its position in shares of Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock valued at $101,000 after purchasing an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC raised its stake in shares of Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after purchasing an additional 1,312 shares during the period.

Analysts Set New Price Targets

Several analysts have commented on the stock. Truist Financial began coverage on shares of Nurix Therapeutics in a research report on Wednesday, July 31st. They issued a "buy" rating and a $36.00 price objective on the stock. Robert W. Baird initiated coverage on Nurix Therapeutics in a research note on Friday, September 6th. They issued an "outperform" rating and a $26.00 price objective on the stock. Oppenheimer raised their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 4th. Stephens restated an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Monday, October 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.40.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,368 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the completion of the sale, the chief financial officer now directly owns 37,270 shares of the company's stock, valued at $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christine Ring sold 5,760 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total transaction of $128,044.80. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $546,680.16. The trade was a 18.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,451 shares of company stock worth $663,160. 7.20% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock traded down $0.56 during mid-day trading on Thursday, hitting $21.23. 563,571 shares of the company traded hands, compared to its average volume of 904,615. Nurix Therapeutics, Inc. has a one year low of $5.68 and a one year high of $29.56. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -7.30 and a beta of 2.20. The stock has a fifty day moving average price of $24.09 and a 200-day moving average price of $21.70.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.